BIOS-08/A - Preclinical development of a 3rd-generation interleukin-2 targeted to inflammatory sites - CUP: J93C23000590006
Scientific-Disciplinary Group
05/BIOS-08 - Molecular Biology
Description
The research aims to develop variants of interleukin-2 (IL-2) fused to antibodies targeting specific oxidation-specific epitopes (OSEs) as a therapeutic tool for cardiac ischemia. OSEs are molecular fragments or lipid modifications that are generated and exposed on the cell surface during tissue damage and inflammatory processes. Regulatory T cells (Tregs) represent important therapeutic targets for autoimmune and inflammatory diseases. Low-dose IL-2 (IL-2LD) stimulates and expands Tregs in vivo. For this reason, firstgeneration IL-2LD therapies are currently being evaluated in numerous clinical trials. In addition, pharmaceutical companies are developing second-generation mutated IL-2 variants with increased half-life and enhanced activity. See the call for further details.
Job posting website
Number of positions
1
Funding body
Università degli Studi di Trieste
How to apply
View the original posting on the MUR website: Go to MUR website